贵州百灵实控人姜伟被立案调查，涉17亿元诉讼

Core Viewpoint - The article discusses the challenges faced by Guizhou Bailing and its actual controller Jiang Wei, including a lawsuit amounting to 1.7 billion yuan and an investigation by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, which have significantly impacted investor confidence [1][4][5]. Group 1: Legal and Regulatory Issues - Jiang Wei has received a notice from the CSRC regarding an investigation into insider trading and violations related to stock transfers, which is a personal investigation and not directly affecting the company's operations [4][5]. - The company’s stock price fell significantly, with a maximum intraday drop of over 7%, closing at 5.22 yuan per share, down 6.28%, leading the A-share traditional Chinese medicine sector [5]. - A lawsuit from Huachuang Securities against Jiang Wei and others has been accepted by a local court, seeking repayment of 1.4 billion yuan and 361 million yuan related to a financial assistance plan and stock pledge loans [6][10]. Group 2: Company Performance and Financial Health - Guizhou Bailing's revenue reached a historical record of 4.263 billion yuan in 2023, but it reported a net loss of 415 million yuan, marking the first loss since its listing [13]. - The company experienced a significant decline in performance, with a 24.28% year-on-year drop in revenue and a 35.60% decrease in net profit for the first three quarters of the year [13]. - Jiang Wei's personal financial situation has been strained due to extensive investments outside the company, leading to non-operational fund usage from Guizhou Bailing amounting to 1.229 billion yuan in 2020 [13][15]. Group 3: Historical Context and Background - Jiang Wei, the founder of Guizhou Bailing, has a history of building the company into a leading player in the traditional Chinese medicine sector, achieving significant revenue growth in the past [11][12]. - The company was listed in June 2010 and has seen its revenue cross various milestones, peaking at 5.63 billion yuan in net profit in 2018 [11][12]. - Despite past successes, the company has faced continuous scrutiny from regulatory bodies, receiving inquiry letters from the exchange for over ten consecutive years since 2013 [14].